Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep646 | Pituitary and Neuroendocrinology | ECE2022

A clinical case of hypogonadism and anosmia associated with a new mutation of the KAL1/ANOS1 gene: a preliminary report

Del Prete Michela , Sacco Gianleone Di , Bonomi Marco , Vignati Federico , Muratori Fabrizio , Persani Luca

Introduction: Kallmann syndrome (KS) is a genetic condition characterized by the association of anosmia or hyposmia and GnRH deficiency resulting in congenital hypogonadotropic hypogonadism (CHH). Different genes can be implicated in KS, and the most frequent allelic variant occurs in the KAL1/ANOS1 gene in the X-linked form. Differential diagnosis is often made with other rare genetic diseases as CHARGE syndrome (CS) that includes hypogonadism, hyposmia and several organ defe...

ea0099ep423 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Semaglutide therapy in people with type 2 diabetes and obesity: efficacy on glycated hemoglobin and weight loss

Del Prete Michela , Eugenia Disoteo Olga , Cozzi Renato , Di Sacco Gianleone , Vignati Federico , Gavazzi Lidia , Muratori Fabrizio

Introduction: The long acting GLP-1 analogue, Semaglutide (S), is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM). Since November 2021, S has also been approved by the European Medicines Agency (EMA) at a dose of 2.4 mg for the treatment of obesity. Here, we report the efficacy of S, either alone or in combination with other antidiabetic drugs, in patients with T2DM and obesity on glycated hemoglobin (HBA1C) and weight loss.Pat...